PLAINSBORO, N.J., June 4, 2008 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that Accell TBM(R) (Total Bone Matrix) is now available in a smaller size configuration. The addition of the smaller size configuration allows clinicians to use Accell TBM(R) in a broader variety of applications, where smaller amounts of demineralized bone graft matrix are appropriate in a variety of orthopedic applications.
Accell TBM(R) is a novel demineralized bone matrix (DBM). A proprietary process creates a DBM graft material that is moldable without the need for an inert carrier or plasticizer; thereby, the entire product is osteoconductive with osteoinductive potential. Accell TBM(R) can replace the need to harvest bone graft from the iliac crest, sparing the patient additional surgery and postoperative pain. Accell TBM(R) may be used as a bone graft extender in the spine, extremities and pelvis or as a bone void filler for the extremities and pelvis.
"Integra offers some of the most advanced biologics products available for tissue reconstruction. We are committed to expanding our orthobiologic portfolio to better address the needs of orthopedic surgeons and neurosurgeons," said Brian Larkin, President of Integra NeuroSciences.
The U.S. market size for bone graft substitutes in orthopedic spinal procedures is estimated at $350 million (excluding synthetic bone morphogenetic proteins). In 2006, an estimated 450,000 spinal fusion procedures were performed in the United States, including over 200,000 cervical spinal fusions. Additional applications are to be found in orthopedic reconstructive procedures.
Accell TBM(R) is sold in the United States through the Integra OrthoBiologics distributor network consisting of 45 independent distributors with over 300 sales representatives. The Integra OrthoBiologics distributor network is provided additional marketing support by a direct sales team of 22 sales professionals. The Integra OrthoBiologics network already distributes Accell(R), DynaGraft(R), and OrthoBlast(R) demineralized bone matrices as well as the Integra Mozaik(TM) Osteoconductive Scaffold. This extensive product line allows the distributor network to provide a complete range of bone graft substitutes to orthopedic surgeons and neurosurgeons.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Integra Mozaik(TM) Osteoconductive Scaffold, Accell(R), Accell TBM(R) (Total Bone Matrix), Dynagraft(R), and OrthoBlast(R) demineralized bone matrices. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
IART-P